Price$4.67-1.28 (-21.47%)
2026-03-022026-06-03
News · 26 weeks34-33%
2025-12-072026-05-31
Mix2290d
- SEC Filings15(68%)
- Other4(18%)
- Earnings1(5%)
- M&A1(5%)
- Insider1(5%)
Latest news
25 items- SECSCYNEXIS Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - SCYNEXIS INC (0001178253) (Filer)
- SECSCYNEXIS Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events8-K - SCYNEXIS INC (0001178253) (Filer)
- PRSCYNEXIS Announces One-for-Eight Reverse Stock SplitJERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) ("SCYNEXIS"), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-8, effective at 4:05 p.m. ET on May 29, 2026. SCYNEXIS's common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis commencing upon market open on June 1, 2026 under SCYNEXIS's existing trading symbol "SCYX" with a new CUSIP number, 811292 309. The reverse stock split was approved by SCYNEXIS's stockholders at SCYNEXIS's Special Meeting hel
- PRSCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate UpdateCompleted transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)A Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027Completed a private placement with net proceeds of approximately $37.2 million, after deducting placement agent fees and other transaction related expenses, with certain new and existing institutional and accredited investors. Approximately $24 million of the proceeds were received on March 31st with the balance received on April 1stSCYNEXI
- SECSEC Form 10-Q filed by SCYNEXIS Inc.10-Q - SCYNEXIS INC (0001178253) (Filer)
- SECSEC Form EFFECT filed by SCYNEXIS Inc.EFFECT - SCYNEXIS INC (0001178253) (Filer)
- SECSEC Form 424B3 filed by SCYNEXIS Inc.424B3 - SCYNEXIS INC (0001178253) (Filer)
- PRSCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) ("SCYNEXIS" or the "Company"), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that on April 30, 2026, the Compensation Committee of the Company's Board of Directors approved inducement equity awards for a new Vice President in connection with the commencement of employment with the Company. The awards were granted as a material inducement to the employee's acceptance of employment and were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were
- SECSEC Form S-3 filed by SCYNEXIS Inc.S-3 - SCYNEXIS INC (0001178253) (Filer)
- SECSEC Form DEF 14A filed by SCYNEXIS Inc.DEF 14A - SCYNEXIS INC (0001178253) (Filer)
- SECSEC Form DEFA14A filed by SCYNEXIS Inc.DEFA14A - SCYNEXIS INC (0001178253) (Filer)
- SECSEC Form DEF 14A filed by SCYNEXIS Inc.DEF 14A - SCYNEXIS INC (0001178253) (Filer)
- SECSEC Form PRE 14A filed by SCYNEXIS Inc.PRE 14A - SCYNEXIS INC (0001178253) (Filer)
- SECSCYNEXIS Inc. filed SEC Form 8-K: Leadership Update8-K - SCYNEXIS INC (0001178253) (Filer)
- SECSEC Form PRE 14A filed by SCYNEXIS Inc.PRE 14A - SCYNEXIS INC (0001178253) (Filer)
- INSIDERSEC Form 4 filed by Angulo Gonzalez David4 - SCYNEXIS INC (0001178253) (Issuer)
- SECSCYNEXIS Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - SCYNEXIS INC (0001178253) (Filer)
- PRPoxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 MillionPXL770, a first-in-class direct activator of adenosine monophosphate-activated protein kinase (AMPK), is a clinical-stage drug candidate targeting the underlying mechanisms of autosomal dominant polycystic kidney disease (ADPKD) by reducing cyst growth and disease progression Poxel will receive an upfront payment of $8 million, with an additional short-term payment of up to $8 million related to development milestones, and payments of up to $180 million related to commercial milestones A Phase 2 proof-of-concept study in patients with ADPKD is expected to begin in the fourth quarter of 2026, with a first efficacy review expected in the second half of 2027. Regulatory News: POXEL
- SECSCYNEXIS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure8-K - SCYNEXIS INC (0001178253) (Filer)
- SECSCYNEXIS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure8-K - SCYNEXIS INC (0001178253) (Filer)
- PRSCYNEXIS Announces $40.0 Million Private PlacementJERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) ("SCYNEXIS" or the "Company"), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors. The Company anticipates upfront gross proceeds from the private placement to be approximately $40.0 million, before deducting placement agent fees and transaction-related expenses, and up to an additional $52.2 million in gross proceeds if the Common Warrants a
- PRSCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progressionA Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027With this acquisition, SCYNEXIS strengthens its mission to develop innovative solutions for severe and rare diseases, unlocking further opportunities for value creation SCYNEXIS will host a conference call on March 31, 2026 at 8:30 a.m. ET to provide a corporate update. JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a
- PRSCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate UpdateSCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026 Responding to patients' need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years JERSEY CITY, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneerin
- SECSEC Form 10-K filed by SCYNEXIS Inc.10-K - SCYNEXIS INC (0001178253) (Filer)
- PRSCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the first participants have been dosed in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial evaluating the intravenous formulation (IV) of its second-generation triterpenoid antifungal therapy, SCY-247, which is being developed as a treatment for invasive candidiasis (IC) and as a prophylaxis therapy for invasive fungal disease. Results from this trial are expected in 2026. "Following the FDA's recent decision to grant SCY-247 bot
SCYX FAQ
6 questionsWhat does SCYNEXIS Inc. do?
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai)...Where does SCYX stock trade?
SCYNEXIS Inc. (SCYX) is listed on NASDAQ.What sector and industry is SCYX in?
SCYNEXIS Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did SCYNEXIS Inc. go public?
SCYNEXIS Inc. (SCYX) completed its IPO in 2014.What companies are similar to SCYX?
Notable peers in the same industry include INTT (inTest Corporation), CDTX (Cidara Therapeutics Inc.), SACH (Sachem Capital Corp.), NBSE (NeuBase Therapeutics Inc.). Compare SCYX side-by-side with any of them on Quantisnow.How can I track SCYX on Quantisnow?
Quantisnow aggregates SCYNEXIS Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SCYX to receive live email and push alerts on every new disclosure.